| Literature DB >> 25439988 |
Frédérique Penault-Llorca1, Anne Vincent-Salomon1, Gaëtan MacGrogan1, Pascal Roger1, Isabelle Treilleux1, Alexander Valent1, Marie-Christine Mathieu1, Martine Antoine1, Véronique Becette1, Catherine Bor1, Eva Brabencova1, Emmanuelle Charafe-Jauffret1, Marie-Pierre Chenard1, Marie-Mélanie Dauplat1, Paul Delrée1, Mojgan Devouassoux1, Maryse Fiche1, Marie-Eve Fondrevelle1, Viviana Fridman1, Christian Garbar1, Pascal Genin1, Jean-Pierre Ghnassia1, Juliette Haudebourg1, Sophie Laberge-Le Couteulx1, Delphine Loussouarn1, Aurélie Maran-Gonzalez1, Myriam Marcy1, Patrick Michenet1, Bruno Poulet1, Christine Sagan1, Martine Trassard1, Véronique Verriele1, Laurent Arnould1, Magali Lacroix-Triki2.
Abstract
International guidelines on HER2 determination in breast cancer have just been updated by the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP), on the basis of more than ten-year practice, results of clinical trials and concordance studies. The GEFPICS group, composed of expert pathologists in breast cancer, herein presents these recommendations, adapted to the French routine practice. These guidelines highlight the possible diagnosis difficulties with regards to HER2 status determination, such as intra-tumor heterogeneity, special histological subtypes and biomarker re-evaluation during metastatic relapse. Pre-analytical issues and updated scoring criteria (especially for equivocal cases) are detailed, in order to decrease the occurrence of false negative cases. In the era of personalized medicine, pathologists are more than ever involved in the quality of oncotheranostic biomarker evaluation.Entities:
Keywords: Breast cancer; Cancer du sein; Guidelines; HER2; Hybridation in situ; Immunohistochemistry; Immunohistochimie; In situ hybridization; Recommandations
Mesh：
Substances：
Year: 2014 PMID： 25439988 DOI： 10.1016/j.annpat.2014.08.018
Source DB: PubMed Journal: Ann Pathol ISSN： 0242-6498 Impact factor: 0.407